摘要
目的观察阿莫西林克拉维酸钾片治疗急性咽扁桃体炎的疗效和安全性。方法选择2015年2月至2017年5月在我院进行急性咽扁桃体炎治疗的302例患者为研究对象,按照随机数字法分成对照组和观察组,每组各151例。对照组给予注射用克林霉素磷酸酯静脉滴注治疗,观察组给予阿莫西林克拉维酸钾片治疗。比较两组患者治疗后满意度、效果及用药安全性。结果用药后观察组患者在咽痛、发热、扁桃体及咽部充血方面缓解时间均低于对照组,比较组间差异具有统计学意义(P<0.05);用药后对照组患者临床总有效率明显低于观察组,比较组间差异具有统计学意义(P<0.05);用药后对照组患者不良反应总发生率明显高于观察组,比较组间差异具有统计学意义(P<0.05);用药后对照组患者临床治疗总满意率明显低于观察组,比较组间差异具有统计学意义(P<0.05)。结论阿莫西林克拉维酸钾片治疗急性咽扁桃体炎疗效显著,不良反应情况发生少,安全性高,值得临床推广。
Objective To observe the efficacy and safety of Amoxicillin and Clavulanate Potassium in acute pharyngo-amygdalitis.Methods 302 acute pharyngo-amygdalitis patients treated from February 2015 to May 2017 in our hospital were selected and randomly assigned to two groups,151 cases in each group.The control group took the intravenous dripping of Clindamycin Phosphate;the observation group took Amoxicillin and Clavulanate Potassium tablets.The clinical satisfaction,therapeutic effect and safety were compared.Results After treatment,the relief time of pharyngalgia,fever,tonsil and pharyngeal hyperemia in the observation group was shorter than control group(P<0.05);the total effective rate in the control group was lower than observation group(P<0.05);the overall adverse event rate in the control group was higher than observation group(P<0.05);the satisfaction in the control group was lower than observation group(P<0.05).Conclusion Amoxicillin and Clavulanate Potassium can remarkably reduce the adverse event rate and increase the clinical safety.It is worthy of clinical promotion.
作者
姜辉道
JIANG Hui-dao(Qingdao Jimo District Yifengdian Health Center,Qingdao 266224,China)
出处
《中国医药指南》
2020年第14期1-3,共3页
Guide of China Medicine
关键词
安全性
急性咽扁桃体炎
疗效
阿莫西林克拉维酸钾片
静脉注射
Safety
Acute pharyngo-amygdalitis
Efficacy
Amoxicillin and Clavulanate Potassium tablets
Intravenous injection
